Breaking News, Financial News

Financial Report: GlaxoSmithKline

GlaxoSmithKline

4Q Revenues: $12.1 billion (+5%)

4Q Earnings: $2.2 billion (-6%)

FY Revenues: $45.4 billion (+6%)

FY Earnings: $10.6 billion (+4%)
 
Comments: Advair sales were $7.0 billion for the year (+15%) and $1.9 billion in the quarter (+12%). Lamictal sales were $2.2 billion for the year (+22%) and $610 million in the quarter (+22%). Avandia sales dropped 31% to $1.8 billion for the year, and $327 million in the quarter (-48%), due to reports that linked the drug to an increased risk of heart attacks. Restructuring costs were $522 million in the quarter. R&D expenses for the year were $6.7 billion (+5%), and $2.1 billion in the quarter (+11%).

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters